

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 March 2001 (08.03.2001)

PCT

(10) International Publication Number
WO 01/15767 A1

(51) International Patent Classification⁷: A61M 31/00

(21) International Application Number: PCT/US00/23339

(22) International Filing Date: 23 August 2000 (23.08.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

09/384,860 27 August 1999 (27.08.1999) US

09/425,826 22 October 1999 (22.10.1999) US

(71) Applicant (for all designated States except US): CORAZON TECHNOLOGIES, INC. [US/US]; 199 Jefferson Drive, Menlo Park, CA 94025 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CONSTANTZ, Brent, R. [US/US]; 199 Jefferson Drive, Menlo Park, CA 94025 (US). JOHANSSON, Peter, K. [US/US]; 199 Jefferson Drive, Menlo Park, CA 94025 (US). DELANEY, Dave [US/US]; 199 Jefferson Drive, Menlo Park, Ca 94025 (US). MCGURK, Erin [US/US]; 335 Lowell Avenue, Palo Alto, CA 94301 (US).

(74) Agent: FIELD, Bret, E.; Bozicevic, Field & Francis LLP, Suite 200, 200 Middlefield Road, Menlo Park, CA 94025 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:


— With international search report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CATHETER DEVICES AND METHODS FOR THEIR USE IN THE TREATMENT OF CALCIFIED VASCULAR OCCLUSIONS



WO 01/15767 A1



(57) Abstract: Multi-lumen catheter devices/systems (50) and methods for their use in enhancing fluid flow through a vascular site occupied by a vascular occlusion are provided. In a first embodiment, the multilumen catheter devices (51) are made up of a first, second and third lumen, where: (a) the first lumen (44) is used for delivery of an acidic dissolution solution (55) to the vascular site; (b) the second lumen (45) is used for delivery of a buffer solution to the vascular site; and (c) the third lumen (26) is used for removal of fluid from the vascular site. In a second embodiment, the second lumen (45) is not present, such that the subject catheters are made up solely of the first (44) and third lumens (26), i.e. an aspiration catheter (20) and an insert catheter (40), which insert catheter (40), may be either a total or partial insert catheter. In many preferred embodiments, the lumens of the various catheter components are coaxial. Also provided are systems and kits comprising the subject catheter devices.

**CATHETER DEVICES AND METHODS FOR THEIR USE IN THE TREATMENT OF
CALCIFIED VASCULAR OCCLUSIONS**

CROSS-REFERENCE TO RELATED APPLICATIONS

5 This application is a continuation-in-part of and claims priority to application serial no. 09/384,860 filed August 27, 1999 and application serial no. 09/425,826 filed October 22, 1999; the disclosures of which applications are herein incorporated by reference.

INTRODUCTION

10 **Technical Field**

The field of this invention is vascular disease, particularly vascular diseases characterized by the presence of calcified vascular occlusions.

Background of the Invention

15 Vascular occlusions, which may be partial or total occlusions, play a prominent role in many types of vascular disease. Many vascular occlusions encountered in the treatment of vascular disease are characterized by having a mineral component, i.e. they are calcified. Calcified vascular occlusions, both partial and total, are found in both peripheral and coronary vascular disease.

20 A variety of different protocols have been developed for treating vascular diseases characterized by the presence of partial or total occlusions. Such treatment methodologies generally involve mechanical removal or reduction of the size of the occlusion, and include: bypass surgery, balloon angioplasty, mechanical debridement, atherectomy, and the like.

25 Despite the plethora of different treatment strategies that have been developed for the treatment of vascular diseases associated with vascular occlusions, there are disadvantages associated with each technique, such as tissue damage, invasiveness, etc. For example, restenosis is a common complication that results in arteries in which occlusions have been mechanically removed.

30 Calcified vascular occlusions pose significant challenges to currently employed treatment methodologies. For example, where the target vascular occlusion is a total occlusion, it is difficult if not impossible to pass a guidewire through the occlusion, which step is required for many of the currently used procedures. While bypass grafts are sometimes available as alternatives in such instances, bypass procedures have their own risks and complications. Furthermore, if there is no appropriate anastomosis site available, amputation is often the only alternative.

As such, there is continued interest in the development of endovascular methods of treating vascular occlusions. Of particular interest would be the development of methods and devices suitable for use in the treatment of calcified vascular occlusions.

Relevant Literature

5 U.S. Patents of interest include: 4,445,892; 4,573,966; 4,610,662; 4,636,195; 4,655,746; 4,690,672; 4,824,436; 4,911,163; 4,976,733; 5,059,178; 5,090,960; 5,167,628; 5,195,955; 5,222,941; 5,370,609; 5,380,284; 5,443,446; 5,462,529; 5,496,267; 5,785,675; and 5,833,650.

SUMMARY OF THE INVENTION

10 Multi-lumen catheter devices/systems and methods for their use in enhancing fluid flow through a vascular site occupied by a vascular occlusion are provided. In a first embodiment, the multilumen catheter devices are made up of a first, second and third lumen, where: (a) the first lumen is used for delivery of an acidic dissolution solution to the vascular site; (b) the second lumen is used for delivery of a buffer solution to the vascular site; and (c) the third lumen is used for removal of fluid from the vascular site. In a second 15 embodiment, the second lumen is not present, such that the subject catheters are made up solely of the first and third lumens, i.e. an aspiration catheter and an insert catheter, which insert catheter may be either a total or partial insert catheter. In many preferred embodiments, the lumens of the various catheter components are coaxial. In practicing the subject methods, the vascular site is flushed with at least an acidic dissolution fluid for a period of time sufficient for fluid flow through the vascular site to be enhanced, e.g. increased or 20 established. Also provided are systems and kits comprising the subject catheter devices. The subject catheter devices, kits, systems and methods find use in the treatment of a variety of different vascular diseases characterized by the presence of calcified vascular occlusions, including peripheral and coronary vascular diseases.

25 BRIEF DESCRIPTION OF THE FIGURES

Figs. 1A & 1B provide views of a totally occluded and partially occluded vascular site, respectively.

Fig. 2A provides a representation of an aspiration catheter according of an embodiment of the subject invention while Fig. 2B provides a representation of a total occlusion catheter insert for use in the aspiration catheter of Fig. 2A.

30 Fig. 3 provides a representation of a partial occlusion catheter insert for use in the aspiration catheter of Fig. 2A.

Fig. 4 provides a depiction of the use of the partial occlusion catheter system according to the subject invention.

35 Fig. 5 provides a representation of a system according to the subject invention, which system includes a catheter device, manifold, fluid reservoirs, etc.

Figs. 6 to 8 provide a representation of the various stages of the use of the total occlusion system of the subject invention.

Figs. 9 and 10 provide view of alternative embodiments of the subject methods in which external energy is applied to the occlusion, e.g. by movement of a guidewire as shown in Fig. 9.

Fig. 11 provides another view of a total occlusion catheter of the catheter systems of the subject invention.

5 Fig. 12 provides another view of a partial occlusion catheter of the catheter systems of the subject invention.

Fig. 13 provides another view of an aspiration or irrigation catheter of the catheter systems of the subject invention.

10 Figs. 14A and 14B provide representations of the aspiration catheter and the total occlusion insert catheter, respectively, while Fig. 14C provides a representation of the total occlusion insert catheter inserted into the lumen of the aspiration catheter to form a coaxial catheter assembly for use in the methods of the subject invention.

15 Fig. 15A provides a representation of a partial occlusion insert catheter while Fig. 15B provides a representation of the partial occlusion insert catheter inserted into the lumen of the aspiration catheter of Fig. 15A to form a coaxial catheter assembly for use in the methods of the subject invention.

Fig. 16A provides a representation of the use of the coaxial catheter assembly shown in Fig. 2C to flush the surface of a total occlusion; while Fig. 16B provides a representation of the use of the coaxial catheter assembly shown in Fig. 15B to flush the surface of a partial occlusion.

20 Figs. 17A and 17B provide diagrams of systems comprising the coaxial catheter assembly of Fig. 14C and Fig. 15B, respectively.

Figs. 18 to 20 provide a sequential representation of the occluded vessel shown in Fig. 1 being treated according to the subject invention.

Figs. 21 to 22 provide views of alternative embodiments of the subject methods in which external energy is applied to the occlusion, e.g. by movement of a guidewire as shown in Fig. 21.

25

DESCRIPTION OF THE SPECIFIC EMBODIMENTS

Multi-lumen catheter devices/systems and methods for their use in enhancing fluid flow through a vascular site occupied by a vascular occlusion are provided. In a first embodiment, the multilumen catheter devices are made up of a first, second and third lumen, where: (a) the first lumen is used for delivery of an acidic dissolution solution to the vascular site; (b) the second lumen is used for delivery of a buffer solution to the vascular site; and (c) the third lumen is used for removal of fluid from the vascular site. In a second embodiment, the second lumen is not present, such that the subject catheters are made up solely of the first and third lumens, i.e. an aspiration catheter and an insert catheter, which insert catheter may be either a total or partial insert catheter. In many preferred embodiments, the lumens of the various catheter components are 30 coaxial. In practicing the subject methods, the vascular site is flushed with at least an acidic dissolution fluid for a period of time sufficient for fluid flow through the vascular site to be enhanced, e.g., increased or established. Also provided are systems and kits comprising the subject catheter devices. The subject catheter devices, kits, systems and methods find use in the treatment of a variety of different vascular diseases

characterized by the presence of calcified vascular occlusions, including peripheral and coronary vascular diseases.

Before the subject invention is described further, it is to be understood that the invention is not limited to the particular embodiments of the invention described below, as variations of the particular embodiments may be made and still fall within the scope of the appended claims. It is also to be understood that the terminology employed is for the purpose of describing particular embodiments, and is not intended to be limiting. Instead, the scope of the present invention will be established by the appended claims.

It must be noted that as used in this specification and the appended claims, the singular forms "a," "an" and "the" include plural reference unless the context clearly dictates otherwise. Unless defined otherwise all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention belongs.

As summarized above, the subject catheter devices are characterized by being multi-lumen devices, in that they include at least two lumens and often at least three different lumens, depending on whether they are employed to co-administer two different fluids, e.g. a buffer fluid and an acidic dissolution fluid, at substantially the same, if not the same, time. In further describing the various embodiments of the subject invention, the three lumen embodiments will be described first, followed by a description of the two lumen embodiments.

20

I. THE THREE-LUMEN EMBODIMENTS

A. CATHETER DEVICES

1. GENERAL FEATURES

In this embodiment, the subject invention provides multi-lumen catheter devices that include at least 25 three distinct lumens, i.e. the subject devices at least include a first, second and third lumen.

The first lumen is generally located in a first hollow tube and typically is bounded by the inner walls of the first hollow tube, and is characterized in that at least inner walls of the lumen are resistant to reaction with an acidic dissolution fluid, at least for a period of time sufficient for the intended use of the catheter to be completed. More specifically, at least the inner wall of the catheter (i.e. first hollow tube) is fabricated from a material that is resistant to reaction with a solution having a pH of less than about 4, preferably less than about 2 and more preferably less than about 1. As such, the material must be inert to a solution that has a pH from about 0 to 4. Generally, the material from which the inner surface of the first catheter or hollow tube is fabricated must be resistant to reaction with an acidic solution, e.g. must be substantially inert with respect to the acidic dissolution fluid, for a period of time that is at least about 10 min long, preferably at least about 20 min long and more preferably for at least about 1 hour long or longer. Materials of interest from which at least the inner surface of the first lumen may be fabricated include: biocompatible polymers, e.g. polyimide, PBAX™, polyethylene, and the like. The thickness of the inner surface must be sufficient to protect the remainder of the catheter device from any corrosive reaction with the acidic dissolution solution

that is conveyed or delivered through the first lumen during use of the catheter device, as described in greater detail infra. As such, the thickness of the inner wall is typically at least about 0.5 mm, usually at least about 0.1 mm and more usually at least about 0.25 mm. The first catheter or hollow tube of the subject multi-lumen catheter devices is further characterized in that it is capable of being attached in fluid communication, either directly or indirectly, with an acidic dissolution fluid reservoir. The effective total cross sectional area through which acidic dissolution fluid flows during use of the subject devices, (i.e. the total cross-sectional areas of any openings present at the distal end of the first lumen less any area occupied by a blocking element positioned in any of the openings) is sufficient to provide the requisite rate of flushing of the vascular occlusion with the acidic dissolution fluid. Generally, the effective total cross sectional area provided by the at least one opening at the distal end of the first lumen is at least about 0.1 mm², often at least about 0.2 mm² and sometimes at least about 0.3 mm², where the total effective cross sectional area at the distal end of the first lumen may be as large as 0.6 mm² or larger, but in certain embodiments will not exceed about 0.5 mm² and in other embodiments will not exceed about 0.4 mm².

The second lumen of the subject catheter device is generally a second hollow tube or catheter, i.e. it is found inside a second hollow tube or catheter and bounded by the inner walls of the second hollow tube or catheter, and is employed to convey or deliver a pH elevating fluid, e.g. a buffer, to a vascular site, as described in greater detail infra. As such, the second lumen of the subject multi-lumen catheter devices is characterized in that it is capable of being attached in fluid communication, either directly or indirectly, with a pH elevating fluid reservoir. The effective total cross-sectional area of the opening at the distal end of the second lumen, where effective total cross-sectional area is as defined above (e.g. the annular space in a coaxial embodiment, as described in greater detail infra), is sufficient to provide the requisite amount of pH elevating solution to the vascular site so that any portion of the vascular site apart from the target surface of the vascular solution is not contacted with a solution which has a pH of less than about 4, preferably less than about 5 and more preferably less than about 6. Accordingly, the effective cross-sectional area of the opening(s) of the distal end of the second lumen is at least about 0.8 mm², usually at least about 1.4 mm² and may be as large as 2.2 mm² or larger, but generally does not exceed about 2.0 mm² and usually does not exceed about 1.5 mm².

The third lumen of the subject multi-lumen catheter devices is an aspiration lumen. Like the first and second lumens, the third lumen is generally the interior of a hollow tube or catheter and is bounded by the inner walls of this third hollow tube or catheter. The aspiration lumen is characterized by at least having a distal opening(s) with an effective total cross-sectional area (e.g. the area of the annular space in the coaxial embodiments described infra) that is sufficiently large to remove fluid, and debris, from the vascular site at substantially the same rate that fluid (e.g. buffer solution and acidic dissolution solution) is introduced into the vascular site during use of the device, such that the fluid pressure in the vascular site remains substantially isobaric or isometric, where by substantially isobaric or isometric is meant that the fluid pressure in the vascular site does not vary by more than about 50 mm Hg, preferably does not vary by

more than about 10 mm Hg, and more preferably does not vary by more than about 5 mm Hg over the total flushing period.

The subject catheter devices are further characterized by at least including a first vascular occlusion means positioned at some point proximal to the distal end of the outer surface of the catheter device, e.g. the outer surface of the aspiration catheter in the coaxial embodiments described infra. By vascular occlusion means is meant any device or component that is capable of substantially, and preferably completely, occluding a vessel, e.g. an artery or vein. By substantially occluding is meant that fluid, e.g. blood, flow past the occlusion means upon activation is reduced by at least 95%, usually by at least 97% and more usually by at least 99%, where in preferred embodiments, fluid flow is reduced by 100% such that the fluid flow into the vascular site is substantially, if not completely, inhibited. Any convenient means may be employed, where a vascular occlusion means of particular interest includes an inflatable balloon. Inflatable balloons are well known in the catheter art, and any convenient balloon configuration may be employed. While the inflatable balloon may be one that is designed to be inflated with a gas or liquid, of particular interest in many embodiments are those that are configured to be inflated with a liquid, e.g. a pH elevating solution as described in greater detail infra.

2. SPECIFIC ALTERNATIVE EMBODIMENTS

The subject invention provides a number of distinct alternative embodiments of the subject catheter devices. One preferred specific embodiment of interest is a coaxial embodiment, in which each of the first, second and third lumens are coaxial. Other alternative embodiments include embodiments in which at least one of the lumens is not coaxial with the other lumens, as well as embodiments in which none of the lumens is coaxial. Each of these representative alternative embodiments is now described in greater detail below.

a. *Coaxial Embodiments*

As mentioned above, a preferred embodiment of the subject multi-lumen catheter devices is a coaxial embodiment, in which the first, second and third lumens of the subject catheter device are coaxial. By "coaxial" is meant that the first, second and third lumens share a common axis. As such, in these embodiments the first lumen is present in an element positioned inside the second lumen, which in turn is present in an element positioned inside the third lumen. Generally, the first, second and third lumens are found inside fluid delivery means which are positioned inside one another, where the fluid delivery means are often elongated tubular elements, as described above. The coaxially positioned fluid delivery means comprising the first, second and third lumens, i.e. the first, second and third fluid delivery means, may be held in a static relationship with respect to one or another or may be movable with respect to one another, such that at least one of the fluid delivery means, and preferably at least two of the fluid delivery means may be moved without moving the other fluid delivery means--i.e. each of the first, second and third fluid delivery means may be moved independently of one another. Spacers or other means on the inner walls of at least the second and third lumens, and/or the outer walls of the respective fluid delivery means, may be present to maintain the coaxial configuration.

In this coaxial embodiment of the subject invention, one of the lumens serves to deliver an acidic dissolution fluid, one of the lumens serves to deliver a pH elevating fluid and one of the lumens serves to remove fluid from the vascular site. In other words, two of the lumens serve to introduce fluid to the vascular site and one of the lumens serves to remove fluid from the vascular site. While any of the lumens 5 may serve any of the above functions, generally, the first lumen which delivers the acidic dissolution solution (i.e. the one that has at least an inner surface that is substantially inert to the acidic dissolution fluid) is the innermost lumen of the coaxial lumens of the device. As such, the first lumen is the lumen with the inner walls that are closest to the center line or axis of the coaxial catheter device.

The first lumen is generally positioned along the center line or axis of a first elongated fluid delivery 10 means, where the fluid delivery means generally extends along the length of the catheter from its proximal to distal end. The fluid delivery means is typically tubular in shape, and may have a variety of different cross-sectional configurations, including square, triangular, trapezoidal, circular, elliptical, irregular, and the like, where often the cross-sectional shape of the elongated tubular member is curvilinear, and more often is circular.

15 The design of the first fluid delivery means may vary depending on the nature of the target vascular occlusion, e.g. whether the target vascular occlusion is a total occlusion or a partial occlusion. The total occlusion first fluid delivery means, e.g. the total occlusion catheter insert, is an elongated tubular structure, as described above, having a blunt ended, open distal end through which fluid may be flowed under pressure. The length of the total occlusion catheter insert generally ranges from about 90 to 210 cm, usually 20 from about 100 to 190 cm and more usually from about 110 to 150 cm. The outer diameter of the total occlusion catheter insert is such that the catheter insert may be slidably positioned in the second lumen (i.e. the lumen of the second fluid delivery means, as described infra), and typically ranges from about 0.4 to 2.0, usually from about 0.4 to 1.6 mm. The inner diameter of the total occlusion catheter insert typically ranges from about 0.2 to 1.0, usually from about 0.25 to 1.0 and more usually from about 0.3 to 1.0 mm.

25 Where the target occlusion is a partial occlusion, a partial occlusion first fluid delivery means is employed, i.e. a partial occlusion catheter insert. The partial occlusion catheter insert differs from the total occlusion catheter insert in a number of ways. First, the partial occlusion catheter insert includes a balloon or analogous vessel occlusion means at its distal end, where the distance between the vascular occlusion means and the distal end of the catheter insert typically ranges from 1 to 30 mm, usually from about 10 to 20 mm. 30 Second, the partial occlusion vascular insert has one or more fluid introduction ports proximal to the proximal side of the distal balloon. The diameter of the infusion ports may vary, but typically ranges from about 0.2 to 1.2, usually from about 0.4 to 1.0 and more usually from about 0.5 to 0.8 mm. Where the vascular occlusion means on the partial occlusion catheter insert is a balloon, a balloon inflation lumen is also present in the partial occlusion catheter insert. Finally, the end of the partial occlusion catheter insert is 35 sealed. The length of the partial occlusion catheter insert generally ranges from about 90 to 250 cm, usually from about 100 to 230 cm and more usually from about 110 to 190 cm. The outer diameter of the partial occlusion catheter insert is such that the catheter insert may be slidably positioned in the second lumen, i.e. the lumen of the second fluid delivery means, as described infra. The outer diameter typically ranges from

about 0.5 to 2.0. The inner diameter of the partial occlusion catheter insert typically ranges from about 0.2 to 1.0, usually from about 0.25 to 1.0 and more usually from about 0.3 to 1.0 mm.

The above described partial and total catheter inserts are further characterized by being capable of being attached at their proximal ends, either directly or through one or more attachment means, which may 5 include stop cocks, Touhy-Borst valves, luer valves, etc., to a fluid reservoir, e.g. an acidic dissolution fluid reservoir and, in the case of the partial occlusion catheter insert, a balloon inflation means. A representation of a total occlusion catheter insert 30 according to the subject invention is provided in Fig. 2B. A representative partial occlusion catheter insert is provided in Fig. 3. In Fig. 3, partial occlusion catheter insert 40 includes elongated tubular structure 42 that is sealed at its distal end 48. Proximal to the distal end 48 is 10 balloon 46, where the distance Y typically ranges from about 1 to 30 mm, usually from about 10 to 20 mm. Also depicted are infusion ports 44. The diameter of the infusion ports may vary, but typically ranges from about 0.2 to 1.2, usually from about 0.4 to 1.0 and more usually from about 0.5 to 0.8 mm. Also shown is 15 balloon inflation lumen 43, where the balloon inflation lumen has dimensions similar to those of balloon inflation lumen 23. As evidenced, the partial occlusion catheter insert includes two lumens, a fluid introduction lumen and a balloon inflation lumen. Also visible in Figs. 2B and 3 is second delivery means 35 which includes the second lumen, described in greater detail below.

The second lumen of the subject multi-lumen catheter devices is designed for delivery of a pH elevating solution to the vascular site of the target occlusion. This lumen is generally present in a second fluid delivery means (element 35 in Figs. 2B and 3), where the fluid delivery means is generally an 20 elongated tubular structure analogous to the first fluid delivery means described supra. In the present coaxial embodiment, the dimensions of this second fluid delivery means, i.e. second catheter insert, are such that the first fluid delivery means or catheter insert described above (i.e. either the partial or total occlusion catheter insert) can fit inside this second fluid delivery means, i.e. can fit inside the lumen of the second fluid delivery means. A further limitation is that the first fluid delivery means must fit inside the second fluid 25 delivery means in a manner such that an annular space is formed in the second lumen which is sufficient to convey the requisite amount of pH elevating fluid to the vascular site during use of the device. As such, the inner diameter of the second lumen exceeds the outer diameter of the first fluid delivery means by at least about 0.6 mm, sometimes at least about 0.9 mm and in certain embodiments at least about 1.2 mm. Accordingly, the inner diameter of the second fluid delivery means ranges from about 0.8 to 2.5, usually 30 from about 0.9 to 1.9 and more usually from about 1.0 to 1.3 mm. The second fluid delivery means has an open distal end which, when positioned around the first fluid delivery means during use, forms an annular opening through which pH elevating fluid flows out of the second fluid delivery means and into the vascular site during use. The total effective cross-sectional area of the annular opening typically ranges from about 0.6 to 2.6, usually from about 0.8 to 1.9 and more usually from about 0.9 to 1.3 mm². The overall length of 35 the second fluid delivery means typically ranges from about 90 to 210, usually from about 100 to 190 and more usually from about 110 to 150 cm. The second fluid delivery means is further characterized by having a means for connecting to a pH elevating fluid reservoir, either directly or

indirectly, at its proximal end, where such means may include, where desired, a luer valve, Touhy-Borst valve, stop cock, etc.

The first and second lumens and their respective fluid delivery means may be combined into integrated catheters in certain embodiments. An example of a total occlusion catheter unit is presented in 5 Fig. 11 while an example of a partial occlusion catheter unit is presented in Fig. 12.

The third lumen in this coaxial embodiment of the subject devices is the outermost lumen, which is generally present in an elongated tubular structure analogous to the first and second fluid delivery means, as described above. The third lumen present in this third fluid delivery means is employed to remove fluid from the vascular site. As such, this third fluid delivery means is properly viewed as an aspiration catheter. The 10 aspiration catheter is generally an elongated tubular structure fabricated from a flexible, biologically acceptable material having a balloon or analogous vessel occlusion means positioned at its distal end. The length of the aspiration catheter may vary, but is generally from about 80 to 200 cm, usually from about 90 to 180 cm and more usually from about 100 to 140 cm. The outer diameter of the aspiration catheter is selected so as to provide for access of the distal end of the catheter to the vascular site via the vascular 15 system from the remote point of entry, where the outer diameter typically ranges from about 1.0 to 4.0 mm (3 to 12 Fr), usually from about 1.5 to 3.0 mm (4.5 to 9.0 Fr) and more usually from about 1.7 to 2.7 mm (5 to 8 Fr). The aspiration catheter is characterized by having an open distal end, where the inner diameter at the open distal end is sufficient to house the first and second coaxial fluid delivery means, as described supra, and remove fluid from the vascular site at the desired rate, e.g. a rate that provides for substantially 20 isometric or isobaric pressure in the vascular site during treatment, through the resultant annular space. The inner diameter of the third or aspiration lumen, at least at its distal end and generally along the entire length of the aspiration catheter, typically ranges from about 0.2 to 2.0, usually from about 0.25 to 1.75 and more usually from about .35 to 1.5 mm. The total effective cross-sectional area at its distal end, i.e. the cross-sectional area of the annular space at the distal end opening, typically ranges from about 1.3 to 3.9, usually 25 from about 1.3 to 3.2 and more usually from about 1.3 to 2.5 mm². Also present at the distal end of the aspiration catheter is a vessel occlusion means, where the vessel occlusion means is usually an inflatable balloon. The balloon is one that is inflatable to a volume sufficient to substantially occlude the vessel in which the aspiration catheter is positioned, e.g. by pressing against the intimal surface of the vessel in which the aspiration catheter is positioned. The balloon is in fluid or gaseous communication with an inflation 30 lumen that runs the length of the aspiration catheter and can be connected to a balloon inflation means. The inflation lumen has an inner diameter that typically ranges from about 0.1 to 0.5, usually from about 0.2 to 0.4 mm. In certain embodiments, the aspiration catheter further includes a separate guidewire lumen. When present, the guidewire lumen has a diameter ranging from about 0.2 to 1.0 mm, usually from about 0.3 to 0.6 mm. Thus, the aspiration catheter includes at least two distinct lumens, i.e. an aspiration lumen (also referred 35 to herein as the third lumen) and a balloon inflation lumen, and in many embodiments includes three distinct lumens, i.e. an aspiration lumen, a balloon inflation lumen and a guidewire lumen. A representation of an aspiration or irrigation catheter is provided in Fig. 13.

The aspiration catheter is further characterized by being capable of attaching, either directly or through one or more attachment means, at its proximal end to vacuum means, e.g. a negative pressure means, where such means is sufficient to provide for the desired aspiration during use of the device, and a balloon inflation means, where such means is sufficient to inflate the balloon at the distal end of the catheter when desired, and may include any of the specific features and valves, as described above.

A representation of the aspiration catheter of the subject catheter systems found in the subject kits is provided in Fig. 2A. In Fig. 2A, aspiration catheter 20 includes elongated tubular member 22 and balloon 24 located proximal to the distal end. The distance X between the distal most portion of the balloon 24 and the distal end of the catheter typically ranges from about 1 to 20, usually from about 5 to 10 mm. Also shown is distal open end 26 through which either the partial or total occlusion insert catheter is moved and fluid is aspirated. Balloon 24 is inflatable via balloon inflation lumen 23.

b. *Alternative Embodiments*

In an alternative embodiments of the subject invention, at least two of the first, second and third lumens are not coaxial. In these alternative embodiments, the configuration of the first, second and third lumens in the device may vary greatly. For example, the first second and/or third lumens may be present on separate non-coaxial fluid delivery means. As such, the device could be made up of three different fluid delivery means bundled together to produce a triple lumen catheter device. Alternatively, a single fluid delivery means could house all three lumens. In certain embodiments, two of the lumens, i.e. the first and second lumen, will be present on a first fluid delivery means, which fluid delivery means is coaxially positioned within the third lumen. The first or internal fluid delivery means housing the first and second lumens may take on a variety of configurations. In one configuration, the first and second lumens terminate or open at the distal end of the internal fluid delivery means. In other configurations, one of the lumens opens at a different area from the other lumen. In these embodiments, the first lumen typically opens at the distal end of the internal fluid delivery means and the second lumen opens at a site proximal to the distal end of the internal fluid delivery means. The second lumen may open up at one or more openings proximal to the distal end of the internal fluid delivery means. In each of these embodiments, the internal fluid delivery means housing the first and second lumens is present in a third lumen which is also housed by a fluid delivery means, where this fluid delivery means may be referred to as an aspiration catheter, as described above.

B. CATHETER SYSTEMS

As summarized above, the subject invention also provides catheter systems suitable for use in the subject methods, as described in greater detail infra. By catheter system is meant two or more disparate catheter components which are capable of being assembled into a single unit, i.e. coaxial catheter assembly, having at least an inner catheter that is slidably positioned within the lumen of an outer catheter, i.e. a coaxial catheter assembly having an inner insert catheter that can be moved relative to the outer catheter so as to produce varying distances between the distal ends of the two coaxial catheters. For example, a catheter system which

includes the above described coaxial embodiments where all three first, second and third lumens are coaxial, will include disparate catheter fluid delivery means that fit within one another to produce a coaxial triple lumen catheter as described above. In such systems, the system will at least include an aspiration catheter, a pH elevating fluid delivery catheter and at least one internal fluid delivery catheter. In many systems
5 according to this embodiment, the system will further include a second internal catheter, such that the first internal catheter is suitable for use in treating total occlusions and the second internal catheter is suitable for use in treating partial occlusions. An exemplary catheter system of the subject invention includes the partial occlusion catheter unit, the total occlusion catheter unit and the irrigation or aspiration catheter unit depicted in Figs. 11 to 13.

10

C. FURTHER CATHETER DEVICE AND SYSTEM CHARACTERISTICS

The components of the subject catheter systems and catheter devices, as described above, may be fabricated from any convenient material, with the only limitation being that at least the inner surface of the first lumen be fabricated from a material that withstands, i.e. does not degrade upon contact with, the acidic dissolution fluid, at least for the period of time during which the catheter system is used. The materials must also be able to withstand the effects of any reaction byproducts produced by contact of the acidic dissolution solution with the components of the target occlusion. Suitable materials include biocompatible polymers, e.g. polyimide, PBAX™, polyethylene, and the like. Any glues or fittings that are employed must also be able to meet the same criteria. Any convenient fabrication protocol may be employed, where numerous
15 suitable protocols are known to those of skill in the art.
20

D. METHODS

Also provided by the subject invention are methods of locally introducing active agents to vascular sites. In the broadest sense, the subject catheter systems may be employed to introduce any active agent in a
25 fluid delivery vehicle to a vascular site. The subject systems achieve local delivery of active agents in fluid delivery vehicles by irrigating or flushing a portion of the vascular system with the fluid agent composition. Active agents of interest that may be locally introduced using the subject methods include: thrombolytic agents, growth factors, cytokines, nucleic acids (e.g. gene therapy agents), detergents and surfactants, and the like. Of particular interest is the use of the subject catheter systems in the treatment of vascular calcified
30 occlusions, which application will now be described in greater detail as representative of the various methods in which the subject catheter systems may be introduced.

For treatment of vascular calcified occlusions with the subject catheter devices and systems, the subject catheter systems are used to flush a surface of the target vascular occlusion with an acidic dissolution fluid for a period of time sufficient for fluid flow to be enhanced through the vascular site. As indicated above, by enhanced is meant that fluid flow is either established in situations where fluid flow is not initially present, e.g. where the target vascular occlusion is a total occlusion, or increased where some fluid flow through the vascular site is present, e.g. in situations where the vascular site is occupied by a partial occlusion. The subject methods are further characterized in that, simultaneously with the acidic dissolution
35

fluid, a pH elevating fluid is also introduced into the vascular site of the target lesion, i.e. the target vascular site. A critical feature of the subject methods is that the subject devices are used to introduce both acidic dissolution fluid and pH elevating fluid to the target vascular site in a manner such that the acidic dissolution fluid primarily contacts the surface of the target occlusion, with the remainder of the target vascular site being contacted with fluid that has a pH which is much higher than that of the acidic dissolution fluid.

5 1. *The Target Vascular Site*

The target site through which fluid flow is enhanced by the subject methods is a site within a vessel, typically an artery or vein, and usually an artery. In many embodiments, the vascular site is a peripheral vascular site, by which is meant that the vessel in which the vascular site is located is a vessel found in one of the extremities of the patient to be treated, i.e. the arms or legs. Often, the vascular site is a site in a lower extremity vessel, e.g. a lower extremity artery. As indicated above, of particular interest in certain embodiments are peripheral arterial vascular sites, where specific peripheral arteries of interest include: iliac arteries, femoropopliteal arteries, infrapopliteal arteries, femoral arteries, superficial femoral arteries, popliteal arteries, and the like. In yet other embodiments, the vascular site is present in a heart associated vessel, e.g. the aorta, a coronary artery or branch vessel thereof, etc. In yet other embodiments, the vascular site is present in a carotid artery or a branch vessel thereof.

The vascular site is occupied by a vascular occlusion in such a manner that fluid flow through the vascular site, e.g. blood flow, is at least impeded if not substantially inhibited. By at least impeded is meant that fluid flow is reduced by at least 20 %, usually by at least 50% and more usually by at least 80 % through the vascular site as compared to a control. In such situations, the vascular site is occupied by a partial vascular calcified occlusion. By substantially inhibited is meant that substantially no fluid flows through the vascular site. For purposes of this invention, fluid flow through a vascular site is considered to be substantially inhibited where it is not possible to pass a guidewire through the vascular site, where the guidewire has a diameter ranging from .014 to .038 in and is applied to the site with a pressure ranging from about 1 to 30 oz.

A representation of a peripheral artery having a vascular site occupied by a total vascular calcified occlusion is provided in Fig. 1A while a representation of a peripheral artery having a vascular site occupied by a partial vascular calcified occlusion is provided in Fig. 1B. In Figs. 1A & 1B, the external iliac artery 11 is shown as it branches into the SFA 12 and the profunda 13. Also shown are the medial circumflex and the later circumflex, 14 and 15 respectively. The SFA is totally occluded by occlusion 16 in Fig. 1A and partially occluded by occlusion 16 in Fig. 1B.

35 2. *The Target Vascular Occlusion*

The vascular occlusion that occupies the target vascular site is generally a calcified vascular occlusion, by which is meant that the occlusion includes at least some calcium containing component. The calcified occlusion may be a substantially pure mineral structure, or may be a more complex formation that

includes both mineral and other components, including organic matter, e.g. lipids, proteins, and the like. As mentioned above, the target vascular occlusion may be a partial or total vascular occlusion.

The mineral component making up the calcified lesion is generally made up of one or more calcium phosphates, where the calcium phosphates are generally apatitic. The term "apatite" as used herein refers to a group of phosphate minerals that includes ten mineral species and has the general formula $X_5(YO_4)_3Z$, where X is usually Ca^{2+} or Pb^{3+} , Y is P^{3+} or As^{5+} , and Z is F, Cl⁻, or OH. The term calcium apatite refers to a group of phosphate minerals where X is Ca^{2+} . The mineral component of the calcified occlusion typically includes one or more of hydroxyapatite, carbonated hydroxyapatite (dahllite) and calcium deficient hydroxyapatite.

In addition to the mineral component, the calcified occlusion that occupies the target vascular site may also comprise one or more additional components, where such components include: lipids; lipoproteins; proteins; including fibrinogen, collagen, elastin and the like; proteoglycans, such as chondroitin sulfate, heparin sulfate, dermatans, etc.; and cells, including smooth muscle cells, epithelial cells, macrophages and lymphocytes. As such, calcified occlusions that are targets of the subject methods include those that may be described as: type IV, type V and type VI lesions, as defined in Stary *et al.*, Arterioscler. Thromb. Vasc. Biol. (1995)15:1512-1531.

In the vascular occlusions that occupy the target vascular sites of the subject methods, the mineral component of the calcified occlusion generally makes up from about 10 to 100, usually from about 10 to 90 and more usually from about 10 to 85 dry weight % of the occlusion. The size of the occlusion that is the target of the subject methods varies depending on location and specific nature of the occlusion. Generally, the volume of the occlusion will range from about 20 to 10,000 mm³, usually from about 30 to 500 mm³ and more usually from about 50 to 300 mm³.

In certain embodiments, one or both ends of the occlusion may be characterized by being primarily thrombotic material, e.g. a thrombus, where the thrombotic domain of the occlusion extends for about 1 to 5 cm. The nature of the thrombotic domain may be organized or disorganized.

3. *Contacting the Vascular Occlusion with an Acidic Dissolution Fluid*

In the subject methods, one surface of the vascular occlusion, e.g. the distal or proximal surface, is contacted with an acidic dissolution fluid for a period of time sufficient for fluid flow to be established or enhanced through the vascular site. Contact with the vascular site may be accomplished in any convenient manner, so long as it results in the enhancement of fluid flow through the vascular site. Generally, the surface is dynamically contacted or flushed with the acidic dissolution fluid.

By dynamic contact is meant that the fresh dissolution solution is contacted with the surface of the target occlusion one or more times, including continuously, during the treatment period. In many preferred embodiments of the subject methods, the surface of the target occlusion is continuously contacted or flushed with the acidic dissolution fluid. In other words, the acidic dissolution fluid is introduced in a manner such that a continuous flow of the acidic dissolution fluid across the surface of the occlusion is achieved.

Where the surface of the target occlusion is flushed with the dissolution fluid, it is preferred that the pressure in the local environment which includes the surface of the occlusion, i.e. the area bounded by the vessel walls, the surface of the target occlusion and the catheter system used to deliver the solution, remains substantially isometric. By substantially isometric is meant that the pressure in the local environment does not vary by a significant amount, where the amount of variance over the treatment period does not vary by more than about 50 %, usually by not more than about 10 % and more usually by not more than about 5 %. In other words, the local environment remains substantially isobaric during the treatment period. Accordingly, where fluid is dynamically contacted with the surface of the target occlusion, fluid is also simultaneously removed from the local environment comprising the surface of the target occlusion, such that the overall volume of fluid in the local environment remains substantially constant, where any difference in volume at any two given times during the treatment period does not exceed about 50%, and usually does not exceed about 10%. As such, the dissolution fluid is introduced into the local environment of the target lesion in a manner such that the local environment remains substantially isovolumetric.

Where the acidic dissolution fluid is dynamically introduced into the vascular site, the dissolution fluid is introduced in a manner such that the flow rate of the dissolution solution through the vascular site of the lesion is generally at least about 10 cc/min, usually at least about 20 cc/min and more usually at least about 60 cc/min, where the flow rate may be as great as 120 cc/min or greater, but usually does not exceed about 1000 cc/minute and more usually does not exceed about 500 cc/minute, where by "volume" is meant the local environment of the occlusion, as defined above. The total amount of dissolution fluid that is passed through the local environment of the lesion during the treatment period typically ranges from about 100 to 1000 cc, usually from about 200 to 800 cc and more usually from about 400 to 500 cc. The solution is generally pressurized to achieve the desired flow rate, as described *supra*. As such, the pressure at the distal end of the coaxial catheter assembly through which the solution is introduced into the local environment typically ranges from about 50 to 1200 psi, usually from about 100 to 600 psi and more usually from about 200 to 400 psi. It is important to note that the overall pressure in the local environment is maintained at substantially isometric or isobaric conditions. As such, the negative pressure at the entrance to the aspiration catheter, e.g. the open annulus at the distal end of the aspiration catheter will be of sufficient magnitude to provide for substantially isobaric conditions. Preferably, the overall pressure in the local environment is maintained at a value ranging from about 0.1 to 3 psi, usually from about 0.5 to 2.5 psi and more usually from about 1 to 2 psi.

As indicated above, a feature of the subject methods of this embodiment is that the target vascular site is flushed with a pH elevating solution concomitantly or simultaneously with the acidic dissolution fluid in a manner sufficient such that only the surface of the target occlusion, and not the remainder of the target vascular site, is contacted with a low pH solution. By pH elevating solution is meant any solution that, upon combination with the acidic dissolution solution, produces a solution with an elevated pH with respect to the acidic dissolution solution. In principle, any fluid that, upon combination of with the acid dissolution fluid produces a solution having a pH higher than that of the acidic dissolution fluid, may be employed, so long as the fluid is biocompatible, at least for the period of time that it is present in the target vascular site. The pH

elevating solution should have a pH of at least about 4, usually at least about 6 and more usually at least about 8. As such, pH elevating fluids of interest include water, physiological acceptable buffer solutions, etc., where in many embodiments, the pH elevating solution is a buffer solution. Representative buffer solutions of interest include: phosphate buffered saline, sodium bicarbonate and the like.

5 In the subject methods, the acidic dissolution and pH elevating fluids are introduced into the vascular site in a manner such that only the target vascular lesion is contacted with the low pH acidic dissolution fluid. As such, the remainder of the target vascular site is contacted with a fluid that has a pH well above that of the acidic dissolution fluid, where the lowest pH to which the remainder of the target vascular site is subjected is not less than 4, preferably not less than 5 and more preferably not less than 6. In
10 other words, only the target vascular occlusion is contacted with the low pH acid dissolution fluid while the remainder of the target vascular site is contacted with a solution the pH of which is not less than 4, preferably not less than 5 and more preferable not less than 6. A representation of a target vascular site being flushed with both an acidic dissolution fluid and a pH elevating fluid according to the subject methods is provided in Figs. 4 , 6 and 11.

15 In Fig 4, where the target lesion is a partial occlusion, a coaxial partial occlusion catheter device, as described above, is introduced into the vascular site such that the balloon 46 of the partial occlusion insert 40 and the balloon 24 of the aspiration catheter 20 flank the partial occlusion 34. Acidic dissolution fluid is introduced by the plurality of ports 44 on the partial occlusion insert. A pH elevating solution is concomitantly introduced through annular space 45. Fluid is then removed from the vascular site by the
20 aspiration catheter 20 through annular space 26. Fig. 6 provides a view of a total occlusion catheter insert flushing a vascular site 12 of a total occlusion 17. As can be seen in Fig. 6, acidic dissolution fluid is introduced through the central catheter and pH elevating solution is introduce via the catheter immediately concentric with the center catheter. Fluid is removed from the vascular site via the aspiration catheter, in which the central and intermediate catheters are coaxially positioned. Because of the manner in which the
25 dissolution fluid and the buffer are administered, pH gradients occur in the vascular site during treatment according to this embodiment of the invention. In the pH gradients that are set up, a center area of low pH extends from the opening of the device to the target lesion, and the pH increases as one moves radially outward from the center area towards the walls of the vascular site, such that at the region next to or adjacent the walls of the vascular site, the pH is not lower than 4, usually not lower than 5 and preferably no lower
30 than 6.

4. Time Period

The surface of the target occlusion is contacted, e.g. flushed, with the acidic dissolution fluid for a period of time sufficient for fluid flow to be enhanced or established through the vascular site, e.g.
35 established or improved. As such, where the target occlusion is a total occlusion, contact is maintained for a period of time sufficient for a guidewire to be passed through the vascular site, as described above. Alternatively, where the target occlusion is a partial occlusion, contact is achieved for a period of time sufficient for the rate of fluid flow to be increased through the vascular site, generally by at least about 10%,

usually by at least about 50%, and in many embodiments by at least about 100 %. Generally, the period of time during which the surface of the occlusion is contacted with the acidic dissolution solution ranges from about 5 to 100 minutes, usually from about 10 to 30 minutes. Where contact is achieved by flushing the target occlusion with the acidic dissolution solution, the contact duration typically lasts for a period of time 5 ranging from about 5 to 30 minutes, usually from about 10 to 30 minutes and more usually from about 10 to 20 minutes.

5. *Acidic Dissolution Solutions*

A variety of different types of acidic dissolution solutions may be employed in the subject methods. 10 The acidic treatment solutions that find use in the subject methods generally have a pH of less than about 6.5, where the pH is usually less than about 4.0 and more usually less than about 3.0. In many preferred embodiments, the pH ranges from 0 to 2, and usually 0 to 1. The acidic treatment solution can include a number of different types of acids, where the acids may or may not include a hydrocarbon moiety, i.e. a hydrogen bonded directly to a carbon atom. Suitable acids that lack a hydrocarbon moiety include halogen 15 acids, oxy acids and mixtures thereof, where specific acids of interest of this type include, but are not limited to, hydrochloric, nitric, sulfuric, phosphoric, hydroboric, hydrobromic, carbonic and hydroiotic acids. For such acids, the acid can be a concentrated acid, or can be diluted. Upon dilution, the concentration of an inorganic acid will generally be from about 10 N to about 0.01 N, preferably between 5 N to 0.1 N. Also of interest are acids that include a hydrocarbon moiety, where such acids include, but are not limited to, any 20 organic acid of one to six (C_1 to C_6) carbons in length. Organic acids of this type include, but are not limited to, formic, acetic, propionic, maleic, butanoic, valeric, hexanoic, phenolic, cyclopentanecarboxylic, benzoic, and the like. For an organic acid, the acid can be in concentrated form, or can be diluted. The acidic treatment solution can be composed of either a monobasic or a polybasic acid. Acids are "monobasic" when they have only one replaceable hydrogen atom and yield only one series of salts (e.g., HCl). Acids are 25 "polybasic" when they contain two or more hydrogen atoms which may be neutralized by alkalies and replaced by organic radicals.

In many embodiments of the subject invention, the acid solution is hypertonic, by which is meant that the osmolarity of the solution is greater than that of whole blood, i.e. the osomolarity is greater than 300 mosmol. The solution may be rendered hypertonic by including any convenient component or components 30 in the solution which provide for the desired elevated osmolarity.

Any convenient agent that is capable of increasing the osmolarity of the solution may be employed, where suitable agents include salts, sugars, and the like. In many embodiments, the agent that is employed to render the solution hypertonic is one or more, usually no more than three, and more usually no more than two, different salts. Generally, the salt concentration in these embodiments of the solution is at least about 35 100 mosmol, usually at least about 200 mosmol and more usually at least about 300 mosmol, where the concentration may be as high as 3000 mosmol or higher, depending on the particular salt being employed to render the solution hypertonic, where the solution may be saturated with respect to the salt in certain

embodiments. Salts that may be present in the subject solutions include: NaCl, MgCl₂, Ringers, etc. where NaCl is preferred in many embodiments.

Of particular interest in many embodiments is the use of a hydrogen chloride solution. In hydrogen chloride solutions that find use in the subject invention, the concentration of HCl in the solution ranges from 5 about 0.001 to 1.0 N, usually from about 0.01 to 1.0 N and more usually from about 0.1 to 1.0 N. In many embodiments, the hydrogen chloride solution will further include one or more salts which make the solution hypertonic, as described above. In certain preferred embodiments, the salt is NaCl, where the concentration of NaCl in the solution is at least 0.05 M, usually at least 0.10 M, and more usually at least 0.15 M, where the concentration may be as high as 0.25 M or higher. In certain embodiments, the solution will be saturated 10 with NaCl.

Of particular interest are aqueous hydrogen chloride solutions that consist of water, hydrogen chloride and NaCl. The concentration of hydrogen chloride in these solutions of particular interest ranges from about 0.01 to 1.0 N, usually from about 0.05 to 0.5 N and more usually from about 0.075 to .25 N. The concentration of NaCl in these solutions of particular interest ranges from about 0.05 to 0.25 M, usually 15 from about 0.05 to .10 M.

6. *Further Embodiments of the Subject Methods*

In a number of embodiments of the subject methods, the methods in which the surface of the target occlusion is contacted with an acidic dissolution fluid may be modified to include a number of additional 20 method steps. Additional method steps that may be present in the overall process include: rendering the local environment of the target occlusion bloodless, contacting the target occlusion with a solution designed to remove organic components, washing or rinsing the local environment of the target occlusion, applying external energy to the target occlusion; imaging the target vascular site; establishing or expanding a passageway through an initial thrombotic domain of the target occlusion; and the like.

25

a. *Rendering the Local Environment Bloodless*

In many preferred embodiments, as described above, the local environment of the target occlusion is rendered substantially bloodless prior to introduction of the acidic dissolution fluid. In these embodiments, the balloon(s) of the assembled catheter system is inflated to physically isolate the local environment from 30 the remainder of the circulatory system and then the local environment is flushed with a physiologically acceptable solution, such that substantially all of the blood present in the solution is removed. Typically, a washing solution will be employed in this step of rendering the local environment bloodless. Examples of washing solutions that may find use in these embodiments include: water for injection, saline solutions, e.g. Ringer's, phosphate buffered saline, or other physiologically acceptable solutions. The washing solution 35 includes an anticoagulant factor in many embodiments, where anticoagulant factors of interest include heparin and the like. The washing solution can also contain chelating agents.

5 b. *Use of Organic Structure Dissolution Solutions*

As mentioned above, in addition to the acidic dissolution solution, certain embodiments of the subject invention include a step of contacting the target occlusion with a dissolution solution which serves to remove at least a portion of the non-mineral, typically organic, phase of the target occlusion. The nature of 5 this 'organic phase dissolution solution' varies depending on the nature of the target occlusion.

Representative active agents that may be present in this organic phase dissolution solution include: oxidizing agents; organic solvents; lipid dissolving agents such as surfactants, e.g. TWEEN™, and detergents, where ionic detergents are of particular interest, e.g. cholic acid, glycocholic acid, benzylkonium chloride; enzymes, and the like.

10

c. *Application of External Energy*

In certain embodiments, external energy is applied to the vascular site to promote mechanical break-up of the occlusion into particles or debris that can be easily removed from the vascular site. Any means of applying external energy to the vascular site may be employed. As such, jets or other such means on a 15 catheter device which are capable of providing varying external forces to the occlusion sufficient to cause the occlusion to break up or disrupt may be employed. Of particular interest in many embodiments is the use of ultrasound. The ultrasound can be applied during the entire time of contact of the cardiovascular tissue with the acidic treatment solution, or the ultrasound can be applied for only part of the treatment period. In one embodiment, ultrasound is applied for several short periods of time while the dissolution treatment 20 solution is contacted with the target occlusion. There are several devices for the application of ultrasound to cardiovascular tissue known to those of skill in the art. See e.g. U.S. Patent No. 4,808,153 and U.S. Patent 5,432,663, the disclosures of which are herein incorporated by reference.

In such methods where external energy is applied to the occlusion in order to disrupt or break-up the occlusion into particles or debris, the particles or debris may range in size from about .01 to 4.0 mm, 25 usually from about 0.1 to 2.0 mm and more usually from about 0.5 to 1.0 mm. In such instances, the method may further include a step in which the resultant particles are removed from the vascular site. Particles may be removed from the vascular site using any convenient means, such as the catheter of the subject invention described in greater detail *infra*.

30

Another means that may be employed to apply external energy to the lesion during the dissolution process is to use a mechanical means of applying external energy. Mechanical means of interest include moving structures, e.g. rotating wires, guidewires, which physically contact the target occlusion and thereby apply physical external energy to the target lesion. See e.g. Figs. 9 and 10.

35 d. *Imaging*

In addition, it may be convenient to monitor or visualize the vascular site prior to or during treatment. A variety of suitable monitoring means are known to those of skill in the art. Any convenient means of invasive or noninvasive detection and/or quantification may be employed. Such means include plain film roentgenography, coronary arteriography, fluoroscopy, including digital subtraction fluoroscopy,

cinefluorography, conventional, helical and electron beam computed tomography, intravascular ultrasound (IVUS), magnetic resonance imaging, transthoracic and transesophageal echocardiography, rapid CT scanning, antioscopy and the like. Any of these means can be used to monitor the vascular site before, during or after contact with the dissolution fluid.

5 In many embodiments, an imaging agent is employed, where the imaging agent may or may not be present in the acidic dissolution solution. Imaging agents of particular interest include: non-ionic imaging agents, e.g. CONRAY™, OXILAN™, and the like.

e. *Thrombus Removal Step*

10 The subject methods may further include a thrombus removal step, e.g. where the calcified domain of the target occlusion is covered by a thrombotic domain, as described above. In such methods, any thrombus removal means that is capable of providing sufficient access of the acidic dissolution solution to the surface the calcified domain of the target lesion may be employed. Thus, where the thrombotic domain is a disorganized domain, it may be sufficient to pass increasingly larger diameter guidewires through the
15 domain until a passageway of sufficient width to provide access of the catheter assembly described above to the surface of the occlusion is established. Alternatively, portions of the thrombotic domain may be removed, e.g. via atherectomy methods, angioplasty methods, and the like, where devices for performing such procedures are known to those of skill in the art. See the patent references cited in the Relevant Literature section, *supra*, which references are herein incorporated by reference.

20

f. *Use of a Plurality of Solutions*

In many embodiments, the subject methods include contacting the surface of the target occlusion with a plurality, i.e. two or more, distinct solutions, one of which is an acidic dissolution solution. Where one or more additional distinct solutions, such as priming solutions, washing solutions, organic phase
25 dissolution solutions and the like are employed, as described below, such disparate solutions are generally introduced sequentially to the vascular site. For example, the target occlusion may be contacted with the following order of solutions: (1) washing solution to render the local environment substantially bloodless; (2) organic phase dissolution solution, e.g. detergent solution such as cholic acid solution, to remove organic phases from the target lesion; (3) acidic dissolution solution to demineralize the target occlusion; and (4) 30 washing solution. Other sequences of solution application can also be employed. See U.S. Patent Application Serial No. 09/353,127, the disclosure of which is herein incorporated by reference. Generally, in any method where a plurality of different solutions are contacted with the target occlusion, a pH elevating solution is introduced simultaneously with at least the acidic dissolution solution, as described above.

35 7. *Outcome*

As discussed above, the subject methods result in the enhancement of fluid flow through the vascular site occupied by the occlusion. Fluid flow is considered to be enhanced in those situations where the vascular site is totally occluded when a guide wire can be moved through the vascular site without

significant resistance. Fluid flow is considered to be enhanced in those situations in which the vascular site is partially occluded when the rate of fluid flow through the vascular site increases by at least 10 %, usually by at least 50 % and in many embodiments by at least 100%.

In certain embodiments, the subject methods will not result in complete removal of the target occlusion from the vascular site. As such, the vascular site, while not totally occluded, may still include lesion deposits on the wall which impede fluid flow through the vascular site and the removal or reduction of which is desired. Any convenient protocol for treating these remaining deposits may be employed, e.g. balloon angioplasty, atherectomy, stenting, etc. Also of interest is the use of two balloon catheters and an acidic dissolution solution, as described in PCT/US99/15918, the disclosure of which is herein incorporated by reference.

Of particular interest in those embodiments where the vascular site is initially totally occluded, fluid flow through the total occlusion is first established using the catheter assembly made up of the total occlusion catheter insert inside the aspiration catheter. Following establishment of fluid flow, the rate of fluid flow is increased using the catheter assembly made up of the partial occlusion catheter insert inside the aspiration catheter.

8. *Additional Applications*

In addition to methods of enhancing fluid flow through a target vascular site, methods and devices are also provided for reducing the mineral content of non-intimal tissue, as described in copending application serial no. 09/382,571, the disclosure of which is herein incorporated by reference. Specifically, the subject invention provides methods and devices that are analogous to those disclosed in the copending application, with the only difference being that the target tissue is contacted simultaneously with both the acidic dissolution solution and a pH elevating solution. As such, the devices are modified such that a means for introducing a pH elevating solution at the same time as the acidic dissolution solution to the target tissue is provided.

E. SYSTEMS

Also provided by the subject invention are systems for practicing the subject methods, i.e. for enhancing fluid flow through a vascular site occupied by a vascular occlusion. The subject systems at least include the catheter systems as described above, a manifold, a fluid reservoir for storing acidic dissolution fluid, a fluid reservoir for storing a pH elevating fluid and a negative pressure means for providing aspiration or suction during use of the system. The systems may further include a number of optional components, e.g. guidewires, pumps for pressurizing the dissolution fluid, and the like. See e.g. U.S. Patent Application No. 09/384,860, the disclosure of which is herein incorporated by reference.

A representative system is provided in Fig. 5. In figure 5, system 50 is characterized by having catheter device 51 in fluid communication with the various fluid and vacuum sources required to practice the methods as described above. Specifically, the outer aspiration catheter 52 of the catheter device 51 is in communication with a medical grad vacuum regulator and vacuum means 53 by aspiration line 53A. The

central or irrigation catheter 54 of the catheter device 51 is in fluid communication with power injector source of acidic dissolution solution, 55. The intermediate catheter of the catheter device 51 is in fluid communication with a source of pH elevating solution 56, e.g. PBS/Hep. Finally, syringe 57 is used to inflate the balloon of the catheter device via the balloon inflation line 58.

5

II. THE TWO LUMEN EMBODIMENTS

A. CATHETER SYSTEMS

As summarized above, the subject invention also provides two lumen catheter devices/systems suitable for delivery of a fluid to a vascular site, and particularly for delivery of an acidic dissolution fluid to 10 a surface of vascular occlusion. By catheter device/system is meant two more disparate catheter components which are capable of being assembled into a single unit, i.e. coaxial catheter assembly, having an inner catheter that is slidably positioned within the lumen of an outer catheter, i.e. a coaxial catheter assembly having an inner insert catheter that can be moved relative to the outer catheter so as to produce varying distances between the distal ends of the two coaxial catheters.

15

1. *Aspiration Catheter*

In this embodiment, the aspiration catheter is generally an elongated tubular structure fabricated from a flexible, biologically acceptable material having a balloon or analogous vessel occlusion means positioned at its distal end. The length of the aspiration catheter may vary, but is generally from about 80 to 20 cm, usually from about 90 to 180 cm and more usually from about 100 to 140 cm. The outer diameter of the aspiration catheter is selected so as to provide for access of the distal end of the catheter to the vascular site via the vascular system from the remote point of entry, where the outer diameter typically ranges from about 1.0 to 4.0 mm (3 to 12 Fr), usually from about 1.5 to 3.0 mm (4.5 to 9.0 Fr) and more usually from about 1.7 to 2.7 mm (5 to 8 Fr). The aspiration catheter is characterized by having an open distal end, where the inner diameter at the open distal end is sufficient to house either a partial or total occlusion insert catheter and remove fluid from the vascular site at the desired rate, e.g. a rate that provides for substantially isometric or isobaric pressure in the vascular site during treatment, through the resultant annular space. The aspiration catheter at least includes an aspiration lumen. The inner diameter of the aspiration lumen, at least at its distal end and generally along the entire length of the aspiration catheter, typically ranges from about 0.2 to 2.0, usually from about 0.25 to 1.75 and more usually from about .35 to 1.5 mm. Also present at the distal end of the aspiration catheter is a vessel occlusion means, where the vessel occlusion means is usually an inflatable balloon. The balloon is one that is inflatable to a volume sufficient to substantially occlude the vessel in which the aspiration catheter is positioned, e.g. by pressing against the intimal surface of the vessel in which the aspiration catheter is positioned. The balloon is in fluid or gaseous communication with an inflation lumen that runs the length of the aspiration catheter and can be connected to a balloon inflation means. The inflation lumen has an inner diameter that typically ranges from about 0.1 to 0.5, usually from about 0.2 to 0.4 mm. In certain embodiments, the aspiration catheter further includes a separate guidewire lumen. When present, the guidewire lumen has a diameter ranging from about 0.2 to 1.0 mm, usually from

about 0.3 to 0.6 mm. Thus, the aspiration catheter includes at least two distinct lumens, i.e. an aspiration lumen and a balloon inflation lumen, and in many embodiments includes three distinct lumens, i.e. an aspiration lumen, a balloon inflation lumen and a guidewire lumen.

A representation of the aspiration catheter of the subject catheter systems found in the subject kits is provided in Fig. 14A. In Fig. 14A, aspiration catheter 120 includes elongated tubular member 122 and balloon 124 located proximal to the distal end. The distance X between the distal most portion of the balloon 124 and the distal end of the catheter typically ranges from about 1 to 20, usually from about 5 to 10 mm. Also shown is distal open end 126 through which either the partial or total occlusion insert catheter is moved and fluid is aspirated. Balloon 124 is inflatable via balloon inflation lumen 123. Finally, device 120 is shown with optional guidewire lumen 128.

The aspiration catheter is further characterized by being capable of attaching, either directly or through one or more attachment means, at its proximal end to vacuum means, e.g. a negative pressure means, where such means is sufficient to provide for the desired aspiration during use of the device, and a balloon inflation means, where such means is sufficient to inflate the balloon at the distal end of the catheter when desired.

2. *Catheter Inserts*

As mentioned above, the subject catheter systems also include at least one catheter insert, where the catheter insert is capable of being slidably positioned within the lumen of the aspiration catheter and is either a total occlusion catheter insert or a partial occlusion catheter insert.

The total occlusion catheter insert is an elongated tubular structure having a blunt ended, open distal end through which fluid may be flowed under pressure. The length of the total occlusion catheter insert generally ranges from about 90 to 210 cm, usually from about 100 to 190 cm and more usually from about 110 to 150 cm. The outer diameter of the total occlusion catheter insert is such that the catheter insert may be slidably positioned in the lumen of the aspiration catheter, and typically ranges from about 0.5 to 2.0, usually from about 0.8 to 1.6 mm. The inner diameter of the total occlusion catheter insert typically ranges from about 0.2 to 1.0, usually from about 0.25 to 1.0 and more usually from about 0.3 to 1.0 mm. The total occlusion catheter insert (as well as the other catheter components of the subject catheter systems) generally has a circular cross-sectional shape, but the cross-sectional shape could be any convenient cross-sectional shape, including ovoid, irregular etc. A representation of a total occlusion catheter insert 130 according to the subject invention is provided in Fig. 14B.

A representation of the total occlusion catheter insert positioned inside the lumen of an aspiration catheter (i.e. as a coaxial catheter assembly) and ready for use in the subject methods, as described *infra*, is provided in Fig. 14C. In the coaxial catheter assembly shown in Fig. 14C, the total occlusion catheter insert and the aspiration catheter are coaxial catheters. In Figure 14C, total occlusion catheter insert 130 is slidably positioned in the lumen of aspiration catheter 120. Also shown is occlusion balloon 124 which is inflated and deflated through fluid/gaseous flow through balloon inflation lumen 123.

Alternatively or in addition to the total occlusion catheter insert described above, the subject catheter systems may also include a partial occlusion catheter insert. The partial occlusion catheter insert differs from the total occlusion catheter insert in a number of ways. First, the total occlusion vascular insert includes a balloon or analogous vessel occlusion means at its distal end. Second, the total occlusion vascular insert has one or more fluid introduction ports proximal to the proximal side of the distal balloon. Finally, the end of the partial occlusion catheter insert is sealed. The length of the partial occlusion catheter insert generally ranges from about 90 to 250 cm, usually from about 100 to 230 cm and more usually from about 110 to 190 cm. The outer diameter of the partial occlusion catheter insert is such that the catheter insert may be slidably positioned in the aspiration lumen of the aspiration catheter, and typically ranges from about 0.5 to 2.0, 5 usually from about 0.8 to 1.6 mm. The inner diameter of the total occlusion catheter insert typically ranges from about 0.2 to 1.0, usually from about 0.25 to 1.0 and more usually from about 0.3 to 1.0 mm.

10 A representative partial occlusion catheter insert is provided in Fig. 15A. In Fig. 15A, partial occlusion catheter insert 140 includes elongated tubular structure 142 that is sealed at its distal end 148. Proximal to the distal end 148 is balloon 146, where the distance Y typically ranges from about 1 to 30 mm, 15 usually from about 10 to 20 mm. Also depicted are infusion ports 144. The diameter of the infusion ports may vary, but typically ranges from about 0.2 to 1.2, usually from about 0.4 to 1.0 and more usually from about 0.5 to 0.8 mm. Also shown is balloon inflation lumen 143, where the balloon inflation lumen has dimensions similar to those of balloon inflation lumen 123. As evidenced, the partial occlusion catheter insert includes two lumens, a fluid introduction lumen and a balloon inflation lumen.

20 Fig. 15B shows the catheter assembly produced by insertion of the partial occlusion catheter into the aspiration catheter. In Fig. 15B, partial occlusion catheter 140 is slidably positioned in the lumen of aspiration catheter 120. As the two catheters are slidably positioned with respect to one another, the distance Z between the two balloons may vary, where during any given treatment procedure the distance Z may range from 1.5 to 45, usually from about 2 to 30 cm. Infusion ports 144 provide for entry of a solution into the 25 occluded space and fluid is then aspirated through the distal end of the aspiration catheter.

The catheter inserts are further characterized by being capable of being attached at their proximal ends, either directly or through one or more attachment means, to a fluid reservoir, e.g. an acidic dissolution fluid reservoir and, in the case of the partial occlusion catheter insert, a balloon inflation means.

30 3. *Further Catheter System Characteristics*

As mentioned in connection with the description of the first three lumen embodiments described above, the components of the subject catheter systems, as described above, may be fabricated from any convenient material, with the only limitation being that at least the catheter inserts and the aspiration catheter be fabricated from a material that withstands, i.e. does not degrade upon contact with, the acidic dissolution 35 fluid, at least for the period of time during which the catheter system is used. The materials must also be able to withstand the effects of any reaction byproducts produced by contact of the acidic dissolution solution with the components of the target occlusion. Suitable materials include biocompatible polymers, e.g. polyimide, PBAX™, polyethylene, and the like. Any glues or fittings that are employed must also be able to

meet the same criteria. Any convenient fabrication protocol may be employed, where numerous suitable protocols are known to those of skill in the art.

While the above described catheter systems have been described in terms of an outer aspiration catheter and a catheter insert which serves to introduce fluid into a vascular site, i.e. as a fluid introduction means, during use of the subject systems (as described in greater detail below) these relative functions may be reversed, such that fluid is introduced through the outer, aspiration catheter and removed through the catheter insert.

B. METHODS

As with the above described three lumen embodiments, the two lumen embodiments of the present invention may be used in locally introducing active agents to vascular sites, and are particularly suited for use in the treatment of vascular calcified occlusions. In using the subject two lumen embodiments to treat vascular calcified occlusions, methods analogous to those described above in connection with the three lumen embodiments are employed, with the only difference being that in the particular methods of this embodiment, a buffer solution is not co-administered with the acidic dissolution solution.

As such, for treatment of vascular calcified occlusions with the subject catheter systems of this particular embodiment, the subject catheter systems are used to flush a surface of the target vascular occlusion with an acidic dissolution fluid for a period of time sufficient for fluid flow to be enhanced through the vascular site. As indicated above, by enhanced is meant that fluid flow is either established in situations where fluid flow is not initially present, e.g. where the target vascular occlusion is a total occlusion, or increased where some fluid flow through the vascular site is present, e.g. in situations where the vascular site is occupied by a partial occlusion.

In the subject methods of this particular embodiment, one surface of the vascular occlusion, either the distal or proximal surface, is contacted with an acidic dissolution fluid for a period of time sufficient for fluid flow to be established through the vascular site. Contact with the vascular site may be accomplished in any convenient manner, so long as it results in the enhancement of fluid flow through the vascular site. Generally, the surface is dynamically contacted or flushed with the acidic dissolution fluid, as described above.

In this embodiment where the acidic dissolution fluid is dynamically introduced into the vascular site, the dissolution fluid is introduced in a manner such that the flow rate of the dissolution solution through the vascular site of the lesion is generally at least about 10 cc/min, usually at least about 20 cc/min and more usually at least about 60 cc/min, where the flow rate may be as great as 120 cc/min or greater, but usually does not exceed about 1000 cc/minute and more usually does not exceed about 500 cc/minute, where by "volume" is meant the local environment of the occlusion, as defined above. The total amount of dissolution fluid that is passed through the local environment of the lesion during the treatment period typically ranges from about 100 to 1000 cc, usually from about 200 to 800 cc and more usually from about 400 to 500 cc. The solution is generally pressurized to achieve the desired flow rate, as described *supra*. As such, the pressure at the distal end of the coaxial catheter assembly through which the solution is introduced into the

local environment typically ranges from about 50 to 1200 psi, usually from about 100 to 600 psi and more usually from about 200 to 400 psi. It is important to note that the overall pressure in the local environment is maintained at substantially isometric or isobaric conditions. As such, the negative pressure at the entrance to the aspiration catheter, e.g. the open annulus at the distal end of the aspiration catheter will be of sufficient magnitude to provide for substantially isobaric conditions. Preferably, the overall pressure in the local environment is maintained at a value ranging from about 0.1 to 3 psi, usually from about 0.5 to 2.5 psi and more usually from about 1 to 2 psi.

The methods by which the subject catheter systems described above are employed to flush a surface of the target occlusion with the acidic dissolution solution are now further discussed in terms of Figs. 16A and 16B. Fig. 16A provides a representation of a catheter assembly according to the subject invention flushing a total occlusion in an artery 136. In Fig. 16A, artery 136 is totally occluded by calcified vascular occlusion 132. Coaxial catheter assembly made up of total occlusion catheter insert 130 inside of aspiration catheter 120 is positioned proximal to one surface of occlusion 132, e.g. by advancement over a guidewire with imaging, as described in the experimental section *infra*. Next, acidic dissolution fluid is introduced through the distal open end of catheter 130, whereby it contacts the proximal surface of the occlusion 132. Simultaneously, fluid is removed from the local environment 138 through the annular space formed at the distal open end 126 of the aspiration catheter 120. The local environment is isolated from the remainder of the host's circulatory system by inflated balloon 124.

Fig. 16B provides a representation of contacting the surface of a partial vascular occlusion using the subject catheter systems. In Fig. 16B, the coaxial catheter assembly that includes partial occlusion catheter insert 146 and aspiration catheter 120 is positioned in the vascular site, e.g. with the aid of a guidewire and imaging, such that the distal end 148 and balloon 146 of the catheter insert are on one side of partial occlusion 134 and the distal end 126 and balloon 124 of aspiration catheter 120 are on the other side of partial occlusion 134. Fluid is then introduced into the local environment (i.e. the space bordered by the arterial walls and the two balloons) through infusion ports 144. Simultaneously, fluid is removed through the annular space present at the distal end 126 of aspiration catheter 120, as indicated by the arrows.

In these embodiments, the surface of the target occlusion is contacted, e.g. flushed, with the acidic dissolution fluid for a period of time sufficient for fluid flow to be enhanced through the vascular site, e.g. established or improved. As such, where the target occlusion is a total occlusion, contact is maintained for a period of time sufficient for a guidewire to be passed through the vascular site, as described above. Alternatively, where the target occlusion is a partial occlusion, contact is achieved for a period of time sufficient for the rate of fluid flow to be increased through the vascular site, generally by at least about 10%, usually by at least about 50%, and in many embodiments by at least about 100 %. Generally, the period of time during which the surface of the occlusion is contacted with the acidic dissolution solution ranges from about 5 to 100 minutes, usually from about 10 to 30 minutes. Where contact is achieved by flushing the target occlusion with the acidic dissolution solution, the contact duration typically lasts for a period of time ranging from about 5 to 30 minutes, usually from about 10 to 30 minutes and more usually from about 10 to 20 minutes.

C. SYSTEMS

Also provided by the subject invention are systems for practicing the subject methods, i.e. for enhancing fluid flow through a vascular site occupied by a vascular occlusion. The subject systems at least include the two lumen catheter systems of this second embodiment, as described above, a manifold, a fluid reservoir for storing acidic dissolution fluid and a negative pressure means for providing aspiration or suction during use of the system. The systems may further include a number of optional components, e.g. guidewires, pumps for pressurizing the dissolution fluid, and the like.

In the system depicted in Fig. 17A, system 150 includes catheter assembly 151, manifold 152 with three entry ports (152a, 152b and 152c), acidic dissolution fluid reservoir 153, negative pressure means 154 and balloon inflation means 155. Catheter assembly 151 is as described in Fig. 14C, having aspiration catheter 120 encompassing total occlusion catheter insert 130. Balloon 124 is positioned on the aspiration catheter at a location proximal to the distal end of the aspiration catheter. Manifold 152 has three ports, 152a, 152b and 152c. Port 152a serves as the balloon port, and is attached to a balloon inflation means 155, e.g. a syringe, during use. The syringe 155 is in fluid or gaseous communication with the interior of balloon 124 through a lumen that extends the length of the aspiration catheter (not shown). Port 152b serves as the guidewire port and injection port, and is attached in fluid communication to acidic dissolution fluid reservoir 153 during use. In certain embodiments, a pumping means (not shown) may be present to provide for desired pressure of the acidic dissolution fluid into the fluid introduction means and out of the distal end of the catheter device 151. Port 152c serves as the aspiration port through which fluid travels from the vascular site through the catheter device 151 and out of the patient. Port 152c is connected to negative pressure means 154 and optionally fluid outflow reservoir (not shown).

The system shown in Fig. 17A is one which is ready for use in the treatment of a total vascular occlusion, as described above. In those embodiments where one wishes to treat a partial vascular occlusion using a catheter assembly having a partial occlusion catheter insert inside an aspiration catheter, as shown in Fig. 15B and 16B, an analogous system as depicted in Fig. 17B is employed. The system depicted in Fig. 17B is analogous to that shown in Fig. 17A. In the assembly shown if Fig. 17B, manifold 152 in an expanded manifold that includes additional port 156 for second balloon inflation means 157.

III. UTILITY

The subject devices and methods of the subject invention as described above find use in a variety of different applications in which it is desired to enhance fluid flow, usually blood flow, (or at least pass a guidewire through), a vascular site that is occupied by a calcified vascular occlusion, e.g. a partial or total occlusion. As such, the subject methods and devices find use in the treatment of peripheral vascular disease, etc. The subject methods also find use in the treatment of coronary vascular diseases. By treatment is meant that a guidewire can at least be passed through the vascular site under conditions which, prior to treatment, it could not. Treatment also includes situations where the subject methods provide for larger fluid passageways through the vascular site, including those situations where fluid flow is returned to substantially the normal rate through the vascular site. The subject methods may be used in conjunction with other methods,

including balloon angioplasty, atherectomy, and the like, as part of a total treatment protocol.

A variety of hosts are treatable according to the subject methods. Generally such hosts are "mammals" or "mammalian," where these terms are used broadly to describe organisms which are within the class mammalia, including the orders carnivore (e.g., dogs and cats), rodentia (e.g., mice, guinea pigs, and rats), lagomorpha (e.g. rabbits) and primates (e.g., humans, chimpanzees, and monkeys). In many embodiments, the hosts will be humans.

IV. KITS

Also provided by the subject invention are kits for use in enhancing fluid flow through a vascular site occupied by an occlusion. The subject kits at least include a catheter device or system, as described above, e.g. a two lumen or three lumen device/system as described above. The kits may further include one or more additional components and accessories for use with the subject catheter systems, including tubing for connecting the various catheter components with fluid reservoirs, syringes, pumping means, etc., connectors, one or more guidewires, dilators, vacuum regulators, etc.

In certain embodiments, the kits further include one or more solutions, or precursors thereof, where in such embodiments the kits at least include an acidic dissolution fluid, such as a hydrochloric acid solution, as described above, where the solution may be present in a container(s), e.g. a flexible bag, a rigid bottle, etc. For kits that are to be used in methodologies in which the fluid is flushed through the local environment of the lesion, the amount of dissolution fluid present in the kit ranges from about 0.5 to 500 liters, usually from about 0.5 to 200 liters and more usually from about 0.5 to 100 liters. In many embodiments, the amount of dissolution fluid in the kit ranges from 0.5 to 5 liters, usually from about 0.5 to 2.0 liters and more usually from about 0.5 to 1.5 liters. Alternatively, the kit may comprise precursors of the dissolution solution for use in preparing the solution at the time of use. For example, the precursors may be provided in dry form for mixing with a fluid, e.g. water, at the time of use. In addition to the dissolution fluid or precursors thereof, the kit may further comprise one or more additional fluids (or dry precursors thereof), such as a priming solution, a washing solution, contrast medium, and the like. In many embodiments, the kits further include at least a pH elevating solution, e.g. a buffer solution such as phosphate buffered saline.

Other elements that may be present in the subject kits include various components of the systems, including manifolds, balloon inflation means, e.g. syringes, pumping means, negative pressure means etc.

In addition to above mentioned components, the subject kits typically further include instructions for using the components of the kit to practice the subject methods with the subject devices. The instructions for practicing the subject methods are generally recorded on a suitable recording medium. For example, the instructions may be printed on a substrate, such as paper or plastic, etc. As such, the instructions may be present in the kits as a package insert, in the labeling of the container of the kit or components thereof (i.e., associated with the packaging or subpackaging) etc. In other embodiments, the instructions are present as an electronic storage data file present on a suitable computer readable storage medium, e.g. CD-ROM, diskette, etc. In yet other embodiments, the actual instructions are not present in the kit, but means for obtaining the instructions from a remote source, e.g. via the internet, are provided. An example of this embodiment is a kit

that includes a web address where the instructions can be viewed and/or from which the instructions can be downloaded. As with the instructions, this means for obtaining the instructions is recorded on a suitable substrate.

5 The following examples are offered by way of illustration and not by way of limitation.

EXPERIMENTAL

- I. Example with Three-Lumen Catheter System
 - A 50 year old male having a total occlusion in the superficial femoral is treated as follows.
 - 10 1. The patient is heparinized using standard procedures.
 2. An introducer sheath is placed either in the same leg to provide retrograde access or in the opposite leg to provide cross-over access.
 3. A guidewire is inserted and advanced to the site of the total occlusion.
 4. The catheter device is inserted so that the distal end of the device is at the vascular site occupied by
 - 15 the total occlusion. The balloon is then inflated by depressing the syringe, such that the balloon occludes the vessel proximal to the occlusion. See Fig. 6.
 5. Contrast medium is then injected into the vascular site to confirm the location of the distal end of the catheter and the inflated balloon.
 6. A sufficient amount of heparinized phosphate buffered saline is then injected through port into the
 - 20 isolated vascular site or local environment and aspirated therefrom such that the isolated local environment is rendered substantially bloodless.
 7. The surface of the total occlusion is then flushed with both an acidic dissolution fluid A (0.1N HCl, 0.05 M NaCl) and a phosphate buffered saline solution at the same time as shown in Fig. 6.
 8. As the occlusion is demineralized, the catheter insert is advanced independent of the aspiration
 - 25 catheter and buffer catheter.
 9. Where desired, the balloon may be deflated, the entire device repositioned, and then balloon may be reinflated to move the distal end of the total occlusion catheter insert to a site further into the occlusion. See Figs. 7 and 8.
 10. Once a passage through the occlusion sufficient to pass a guidewire through the occlusion is
 - 30 produced, the device is removed.
 11. The above procedure results in fluid flow through the vascular site occupied by the lesion being reestablished, as evidenced by passing a guidewire through the vascular site.
 12. Where desired, following reestablishment of fluid flow through the total occlusion, the total
 - 35 occlusion catheter insert is removed. A guidewire is then inserted through the large lumen of aspiration catheter 20 to a space beyond the distal end of the occlusion. A partial occlusion catheter insert is then introduced over the guidewire to a position such that the balloon at the distal end of the insert is on the far side of the partial occlusion. The vascular site is then flushed as shown in Fig. 4 until the desired amount of lesion dissolution is achieved.

II. Variations on the Above Procedure

The above procedure is performed with the additional step of applying mechanical energy to the occlusion during flushing with the acidic dissolution solution. Fig. 9 shows mechanical energy being applied to the occlusion by contacting a guidewire 91 with the surface of the total occlusion during flushing. Fig. 10 shows mechanical energy being applied to the surface of the occlusion with the proximal end of the total occlusion insert. Other means of applying external energy, e.g. mechanical energy, may also be employed.

III. Two Lumen Catheter Systems

A 50 year old male having a total occlusion in the superficial femoral artery (SFA) as shown in Fig. 1 is treated as follows. In Fig. 1, the external iliac artery is shown as it branches into the SFA 12 and the profunda 13. Also shown are the medial circumflex and the later circumflex, 14 and 15 respectively. The SFA is totally occluded by occlusion 16.

1. The patient is heparinized using standard procedures.
2. An introducer sheath is placed either in the same leg to provide retrograde access or in the opposite leg to provide cross-over access.
3. A guidewire is inserted and advanced to the site of the total occlusion.
4. The catheter system as shown in Fig. 17A is employed as follows. The catheter device is inserted so that the distal end of the device is at the vascular site occupied by the total occlusion, as shown in Fig. 18. The balloon 124 is then inflated by depressing the syringe 155, such that the balloon occludes the vessel proximal to the occlusion, as shown in Fig. 18. The local environment 160 bordered by the proximal surface of the occlusion, the SFA vessel walls and the distal surface of the inflated balloon 124 is indicated by dashed lines.
5. Contrast medium is then injected into the vascular site through port 152b to confirm the location of the distal end of the catheter and the inflated balloon.
6. A sufficient amount of heparinized phosphate buffered saline is then injected through port 152b into the isolated vascular site or local environment 160 and aspirated therefrom such that the isolated local environment 160 is rendered substantially bloodless.
7. The surface of the total occlusion is then flushed with acidic dissolution fluid A (0.1N HCl, 0.05 M NaCl) by introducing solution A through port 152b into the vascular space and removing or aspirating fluid from the vascular site through port 152c, as shown in Fig. 18. See also Fig. 16A.
8. As the occlusion is demineralized, the central fluid introduction catheter 130 is advanced independent of the aspiration catheter/outer catheter 120, as shown in Fig. 19.
9. Where desired, balloon 124 may be deflated, aspiration catheter 120 repositioned, and then balloon 124 may be reinflated to move the distal end of the total occlusion catheter insert 130 to a site further into the occlusion 117, as shown in Fig. 20.
10. Once a passage through the occlusion sufficient to pass a guidewire through the occlusion is produced, the device is removed.
11. The above procedure results in fluid flow through the vascular site occupied by the lesion being

reestablished, as evidenced by passing a guidewire through the vascular site.

12. Where desired, following reestablishment of fluid flow through the total occlusion, the total occlusion catheter insert is removed. A guidewire is then inserted through the large lumen of aspiration catheter 120 to a space beyond the distal end of the occlusion. A partial occlusion catheter insert is then introduced over the guidewire to a position such that the balloon at the distal end of the insert is on the far side of the partial occlusion.

5

13. A system as shown in Fig. 17B is then employed to inflate the balloon of the insert, establish a bloodless local environment and flush the remaining partial occlusion with acidic dissolution fluid, as shown in Fig. 16B.

10

IV. Variations on the Above Procedure

The above procedure is performed with the additional step of applying mechanical energy to the occlusion during flushing with the acidic dissolution solution. Fig. 21 shows mechanical energy being applied to the occlusion by contacting a guidewire 191 with the surface of the total occlusion during flushing. Fig. 22 shows mechanical energy being applied to the surface of the occlusion with the proximal end of the total occlusion insert. Other means of applying external energy, e.g. mechanical energy, may also be employed.

15

It is evident from the above discussion and results that improved methods of enhancing blood flow through a vascular occlusion are provided. Specifically, the subject invention provides a means for readily establishing fluid flow through a vascular site totally occluded by a calcified vascular occlusion, which has heretofore been difficult to practice. As such, the subject invention provides a means for using less traumatic procedures for treating peripheral vascular disease, thereby delaying or removing the need for graft procedures and/or amputation. A critical feature of the subject devices and methods is that only the target 20 occlusion is subjected to the low pH conditions of the acidic dissolution solution. As such, unwanted contact of other portions of the target vascular site and/or host are avoided. As such, the subject invention represents a significant contribution to the field.

25

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it is readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

30

WHAT IS CLAIMED IS:

1. A catheter device comprising:
 - at least two lumens, wherein at least one of said lumens is fabricated from a material sufficient for delivery of an acidic dissolution solution; and
 - 5 a first vascular occlusion means.
2. The catheter device according to Claim 1, wherein said device comprises first, second and third lumens.
- 10 3. The catheter device according to Claims 1 or 2, wherein at least two of said lumens are coaxial.
4. The catheter device according to Claim 2, wherein said first, second and third lumens are coaxial.
- 15 5. The catheter device according to Claim 4, wherein said first lumen is present in a first fluid delivery member having a distal end, wherein said first fluid delivery member is movable relative to said second and third lumens.
6. The catheter device according to Claim 4 or 5, wherein said second lumen is present in a second fluid delivery member, where said second fluid delivery member is movable relative to said third lumen.
- 20 7. The catheter device according to Claims 5 or 6, wherein said first lumen is open at said distal end of said first fluid delivery member.
8. The catheter device according to Claims 5, 6 or 7, wherein said first lumen opens at at least one location on said first fluid delivery member at a site proximal to said distal end.
- 25 9. The catheter device according to Claim 8, wherein said first fluid delivery member comprises a second vascular occlusion means at said distal end.
- 30 10. A catheter system comprising:
 - (a) an aspiration catheter comprising an elongated tube having an aspiration lumen ending in an open distal end and an inflatable balloon at said distal end; and
 - (b) a second elongated tube coaxially positioned inside of said aspiration catheter; and
 - (c) at least one of:
 - (i) a total occlusion catheter insert comprising an elongated tube having an open distal end; and
 - (ii) a partial occlusion catheter insert comprising an elongated tube having a sealed distal end, an inflatable balloon at said distal end and at least one infusion port proximal to said inflatable

ballo n;

wherein at least said total and partial occlusion catheter inserts are capable of being slidably positioned within said second elongated tube to produce an annular space at the distal end of said elongated tube through which fluid may flow.

5

11. The catheter system according to Claim 10, wherein said system comprises both said partial and total occlusion catheter inserts.

12. A method of enhancing fluid flow through a vascular site occupied by a vascular occlusion, said 10 method comprising flushing a vascular site with at least an acidic dissolution fluid using a device or system according to any of Claims 1 to 11 for a period of time sufficient for fluid flow to be enhanced through said vascular site.

13. The method according to Claim 12, wherein said method further comprises flushing said vascular 15 site with a buffer solution such that only a surface of said vascular occlusion is contacted with said acidic dissolution fluid and the remainder of said vascular site is not contacted with solution having a pH of less than about 4.

14. A kit for use in enhancing fluid flow through a vascular site occupied by a vascular occlusion, said 20 kit comprising:

a catheter device or system according to Claims 1 to 11.

15. The kit according to Claim 14, wherein said kit further comprises at least one of:

(a) an acidic dissolution solution; and
25 (b) a buffer solution.

1/22




Figure 1A




Figure 1B




Figure 2A




Figure 2B

3/22




Figure 3




Figure 4




Figure 5

6/22




Figure 7




Figure 6

7/22




Figure 8

8/22




Figure 9





Figure 10


9/22




Total Occlusion Catheter
Figure 11




Section A-A
Not to scale






Partial Occlusion Catheter (w/ Balloon)
Figure 12



Irrigation Catheter
Figure 13






Figure 14A




Figure 14B




Figure 14C

14/22




Figure 15A




Figure 15B

16/22




Figure 16A

17/22




Figure 16B

18/22




Figure 17A

19/22




Figure 17B

20/22




Figure 19




Figure 18

21/22




Figure 20




Figure 21




Figure 22

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/23339

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) :A61M 31/00

US CL :604/500

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 604/500, 508, 509, 518, 101.01, 101.05, 102.01, 102.03; 606/192-194, 198

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,462,529 A (SIMPSON et al) 31 October 1995, see entire patent.	1-14 ----

Y		15
A	US 5,207,648 A (GROSS) 04 May 1993, see entire document.	1-15
A	US 4,329,994 A (COOPER) 18 May 1982, see entire patent.	1-15

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance		
E earlier document published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
O document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

02 NOVEMBER 2000

Date of mailing of the international search report

05 DEC 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

JEREMY THISSELL

Telephone No. (703) 308-0858